32 results on '"YAO, J. C."'
Search Results
2. Risk of osteoporosis/osteopenia events in patients newly diagnosed with neuroendocrine tumors.
3. Effect of everolimus treatment on chromogranin A, neuron-specific enolase, gastrin, and glucagon levels in patients with advanced pancreatic neuroendocrine tumors (pNET): Phase III RADIANT-3 study results.
4. Everolimus plus octreotide LAR versus placebo plus octreotide LAR in patients with advanced neuroendocrine tumors (NET): Effect of prior somatostatin analog therapy on progression-free survival in the RADIANT-2 trial.
5. Risk of anxiety/depression events in patients newly diagnosed with neuroendocrine tumors.
6. Everolimus plus octreotide LAR versus placebo plus octreotide LAR in patients (pts) with advanced neuroendocrine tumors: Multivariate analysis of progression-free survival from the RADIANT-2 trial.
7. Everolimus plus octreotide LAR versus placebo plus octreotide LAR in patients with advanced neuroendocrine tumors (NET): Updated safety and efficacy results from RADIANT-2.
8. Effect of everolimus plus octreotide LAR treatment on chromogranin A and 5-hydroxyindoleacetic acid levels in patients with advanced neuroendocrine tumors: Phase III RADIANT-2 study results.
9. Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): Impact of somatostatin analog use on progression-free survival in the RADIANT-3 trial.
10. Everolimus plus octreotide LAR (E+O) versus placebo plus octreotide LAR (P+O) in patients with advanced neuroendocrine tumors (NET): Updated results of a randomized, double-blind, placebo-controlled, multicenter phase III trial (RADIANT-2).
11. Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): Updated results of a randomized, double-blind, placebo-controlled, multicenter phase III trial (RADIANT-3).
12. A prospective, multi-institutional phase II study of GW786034 (pazopanib) and depot octreotide (sandostatin LAR) in advanced low-grade neuroendocrine carcinoma (LGNEC).
13. Somatostatin analogue therapy and PROMIS health-related quality-of-life scores in patients with neuroendocrine tumors.
14. Clinical and demographic characteristics and resource utilization in patients newly diagnosed with neuroendocrine tumors (NET).
15. Relationship between neuroendocrine tumor-related symptoms and PROMIS health-related quality-of-life scores.
16. Neuroendocrine tumor disease state and PROMIS health-related quality of life scores.
17. A phase II study of irinotecan and cisplatin for metastatic or unresectable high grade neuroendocrine carcinoma
18. Population based study of islet cell carcinoma
19. Treatment with bevacizumab (BEV) upregulates expression of the transcription factor Sp1 and its downstream target genes in human carcinoid cells: Molecular basis of the synergistic antiangiogenic activity of bevacizumab and mithramycin A (MIT)
20. Risk factors for low-grade neuroendocrine carcinoma (LGNET): Hospital-based case-control study in US
21. Phase II study of RAD001 (everolimus) and depot octreotide (sandostatin LAR) in advanced low grade neuroendocrine carcinoma (LGNET)
22. Preferential inhibition of Sp1 expression in growing tumors by mithramycin-A (MIT) directly correlates with its potent antiangiogenic effects in human carcinoid xenograft model
23. Association of VEGF expression with poor prognosis among patients with low-grade neuroendocrine carcinoma
24. Phase II study of RAD001 (everolimus) and depot octreotide (Sandostatin LAR) in patients with advanced low grade neuroendocrine carcinoma (LGNET)
25. First-in-human phase-I pharmacokinetic trial of NS-9, a liposomal poly(I):poly(C), in patients with liver metastases from various primary cancers
26. Increased rates of hypertension (HTN) among patients with advanced carcinoid treated with bevacizumab
27. Improved progression free survival (PFS), and rapid, sustained decrease in tumor perfusion among patients with advanced carcinoid treated with bevacizumab
28. Multi-center phase II study of S-1 plus cisplatin in patients with advanced gastric carcinoma (AGC)
29. Pegamotecan (EZ-246), a novel PEGylated camptothecin conjugate, for treatment of adenocarcinomas of the stomach and gastroesophageal (GE) junction: Preliminary results of a single-agent phase 2 study
30. The effect of ethnicity on presentation, pattern of metastasis, and survival in gastric adenocarcinoma at a single center
31. A phase II trial of imatinib in patients with advanced carcinoid tumor
32. Rapid decrease in blood flow (BF), blood volume (BV), and vascular permeability (PS) in carcinoid patients treated with bevacizumab
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.